Beam Therapeutics annual net debt
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Net Debt Growth & History (BEAM)
Beam Therapeutics's net debt was −$140.8M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$140.8M | −$20.3M | — |
| 2024 | 2024-12-31 | −$120.5M | $142.7M | — |
| 2023 | 2023-12-31 | −$263.2M | −$212.5M | — |
| 2022 | 2022-12-31 | −$50.8M | $361.6M | — |
| 2021 | 2021-12-31 | −$412.4M | −$357.8M | — |
| 2020 | 2020-12-31 | −$54.5M | −$48.5M | — |
| 2019 | 2019-12-31 | −$6.0M | — | — |
Beam Therapeutics quarterly net debt
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $27.5M | $154.9M | — |
| Q1 2026 | 2026-03-31 | −$37.5M | $332.3M | — |
| Q4 2025 | 2025-12-31 | −$140.8M | −$20.3M | — |
| Q3 2025 | 2025-09-30 | −$116.5M | −$48.4M | — |
| Q2 2025 | 2025-06-30 | −$127.3M | $197,000 | — |
| Q1 2025 | 2025-03-31 | −$369.8M | −$250.1M | — |
| Q4 2024 | 2024-12-31 | −$120.5M | $142.7M | — |
| Q3 2024 | 2024-09-30 | −$68.1M | −$73.1M | — |
| Q2 2024 | 2024-06-30 | −$127.5M | −$79.1M | — |
| Q1 2024 | 2024-03-31 | −$119.7M | −$48.8M | — |
| Q4 2023 | 2023-12-31 | −$263.2M | −$212.5M | — |
| Q3 2023 | 2023-09-30 | $4.9M | −$17.1M | −77.59% |
| Q2 2023 | 2023-06-30 | −$48.4M | $39.5M | — |
| Q1 2023 | 2023-03-31 | −$70.9M | $75.8M | — |
| Q4 2022 | 2022-12-31 | −$50.8M | $361.6M | — |
| Q3 2022 | 2022-09-30 | $22.0M | $488.6M | — |
| Q2 2022 | 2022-06-30 | −$88.0M | −$18.6M | — |
| Q1 2022 | 2022-03-31 | −$146.7M | −$186.0M | — |
| Q4 2021 | 2021-12-31 | −$412.4M | −$357.8M | — |
| Q3 2021 | 2021-09-30 | −$466.6M | −$363.0M | — |
| Q2 2021 | 2021-06-30 | −$69.4M | $19.7M | — |
| Q1 2021 | 2021-03-31 | $39.4M | $129.7M | — |
| Q4 2020 | 2020-12-31 | −$54.5M | −$48.5M | — |
| Q3 2020 | 2020-09-30 | −$103.6M | — | — |
| Q2 2020 | 2020-06-30 | −$89.1M | — | — |
| Q1 2020 | 2020-03-31 | −$90.3M | — | — |
| Q4 2019 | 2019-12-31 | −$6.0M | — | — |
Beam Therapeutics net debt trends
Over the last five fiscal years, Beam Therapeutics's net debt decreased from −$54.5M to −$140.8M, a change of −$86.3M. The latest reported quarter, Q2 2026, shows $27.5M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...